Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 8/20 | 1.00 |
| ▸ | BRD4 | O60885 | 3/20 | 1.00 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | KAT2B | Q92831 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | BRD1 | O95696 | 3/20 | 0.47 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | PRKCB | P05771 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
| ▸ | PRKACB | P22694 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967380 | 1.00 | BRPF1 (1.00) | BRPF1BRD4BRD9CA12CA9 | |
| Hydrochloric Acid SCHEMBL1236989 | 0.98 | BRPF1 (0.96) | BRPF1BRD4BRD9CA12CA9 | |
| Hydrochloric Acid SCHEMBL30419636 | 0.98 | BRPF1 (0.96) | BRPF1BRD4BRD9CA12CA9 | |
| Hydrochloric Acid SCHEMBL7218030 | 0.96 | BRPF1 (0.92) | BRPF1BRD4BRD9CA12CA9 | |
| Bicarbonate SCHEMBL10970799 | 0.92 | BRPF1 (0.85) | BRPF1BRD4BRD9CA12CA9 | |
| Pyridine SCHEMBL11505119 | 0.87 | BRPF1 (0.76) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL10489571 | 0.79 | BRPF1 (0.63) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL8944339 | 0.78 | BRPF1 (0.63) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL271495 | 0.77 | CA12 (0.63) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL31743122 | 0.77 | BRPF1 (0.61) | BRPF1BRD4BRD9CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | claimed |
| CN-117510407-A | Visible light catalyzed olefin hydrogenation and deuteration method | 瑞博(苏州)制药有限公司 | 2024-02-06 | — | — | CN | claimed |
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | claimed |
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-05-20 | — | — | US | claimed |
| CN-109078656-B | Preparation method of aluminum chloride-loaded methylphenol isomerization catalyst | 西安元创化工科技股份有限公司 | 2021-05-14 | — | — | CN | claimed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| CN-109078656-A | A kind of preparation method for the sylvan isomerization catalyst loading aluminium chloride | 西安元创化工科技股份有限公司 | 2018-12-25 | — | — | CN | claimed |
| CN-108239027-A | The synthetic method of pharmaceutical intermediate 1- methyl -2- quinolinones | 成都卡迪夫科技有限公司 | 2018-07-03 | — | — | CN | claimed |
| CN-105001222-B | 8 [base of 3 amino piperidine 1] Xanthine compounds, its preparation method and purposes as pharmaceutical preparation | 勃林格殷格翰制药两合公司 | 2017-11-07 | — | — | CN | claimed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | claimed |
| WO-2001064246-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH AN HER2 ANTIBODY | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | claimed |
| WO-2001064218-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | claimed |
| WO-2001064197-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTI-TUMOR ANTHRACYCLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | claimed |
| US-6251913-B1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | ZENECA LIMITED (GB) | 2001-06-26 | — | — | US | claimed |
| EP-0971895-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | AstraZeneca AB (SE) | 2000-01-19 | — | — | EP | claimed |
| WO-1998043959-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | ZENECA LIMITED (GB) | 1998-10-08 | — | — | WO | claimed |
| US-5017636-A | Also containing polyisoprene, natural rubber, butadiene-styrene copolymer, wear and heat resistance, resilience | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1991-05-21 | — | — | US | claimed |
| US-4822844-A | MODIFIED WITH NITROGEN COMPOUND CONTAINING EITHER OXYGEN OR SULFUR AS BRANCHING OR END GROUP | THE YOKOHAMA RUBBER CO., LTD. (JP) | 1989-04-18 | — | — | US | claimed |
| US-4647625-A | Process for modifying conjugated diene polymers | NIPPON ZEON CO., LTD. (JP) | 1987-03-03 | — | — | US | claimed |
| US-4616069-A | REACTING THE ALKALI METAL OR ALKALINE EARTH METAL TERMINATED POLYMER WITH TIN COMPOUND AND ORGANIC COMPOUND HAVING AMIDE OR THIOAMIDE LINKAGES | NIPPON ZEON CO., LTD. (JP) | 1986-10-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | BRPF1 2763/4885BRD4 615/4885BRD9 909/4885 |
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | CBR1, POR, CAT | BRPF1 956/4885BRD4 2021/4885BRD9 2851/4885 |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | BRPF1 102/4885BRD4 4/4885BRD9 10/4885 |
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | CBR1, POR, CAT | BRPF1 1021/4885BRD4 2064/4885BRD9 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.